Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

230 targets multiple subtypes of the receptor for somatostatin (sst), a hormone that controls the pituitary gland. Its highest affinity is to sst5, a receptor subtype frequently expressed by the pituitary tumors associated with Cushing's disease. Currently approved somatostatin analogs preferentially bind to sst2 and are not effective in Cushing's disease(6).

SOM230 is currently being studied as a twice-daily sc injection, as well as a long-acting release (LAR) once-monthly intramuscular injection for the treatment of multiple disease types, including Cushing's disease, carcinoid syndrome and acromegaly(10).

Because it is an investigational compound, the safety and efficacy profile of SOM230 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. There is no guarantee that SOM230 will become commercially available(6).

Information about Novartis clinical trials for SOM230 can be obtained by healthcare professionals at www.pasporttrials.com.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "will," "planned," "potential," or similar expressions, or by express or implied discussions regarding regulatory submissions or approvals for SOM230, or the timing of such submissions or approvals, or regarding potential future revenues from SOM230. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with SOM230 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guar
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DIEGO, July 31, 2014 Tandem Diabetes Care®, Inc. ... manufacturer of the t:slim® Insulin Pump, today reported its financial ... In comparing the second quarter of 2014 to the ... to $10.3 million from $5.5 million , t:slim Pump ... In comparing six months ended June 30, 2014 ...
(Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... class action lawsuit (Case #BC4241898) was just filed in Los ... Inc., and GE Healthcare Technologies on behalf of patients who ... brain perfusion scans to diagnose strokes. , Trevor Rees ... a Delaware Corporation; GE Healthcare Technologies, Inc., a corporation; and ...
... EAST RUTHERFORD, N.J., Oct. 20 Cambrex Corporation (NYSE: ... Silver Innovation Award at the 2009 CPhI Event for ... award was accepted by Dr. Jayne E. Muir (Market ... technology to a panel of judges at this important ...
Cached Medicine Technology:Patients Receiving High Radiation at Cedars Sinai File Class Action Lawsuit 2Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 The North America ... market in North America, with analysis and forecast of revenue. ... grow from around $5,021.9 million in 2012 to $6,243 million ... period. , Browse through the TOC of the North America ... in-depth analysis provided. This also provides a glimpse of the ...
(Date:8/1/2014)... Society of America (GSA) the nation,s ... aging has chosen J. Jill Suitor, PhD, ... the Distinguished Career Contribution to Gerontology Award. , ... individual whose theoretical contributions have helped bring about ... original and elegant research designs addressing a significant ...
(Date:8/1/2014)... the nation,s largest interdisciplinary organization devoted to the ... MA, MD, FRCPI, AGSF, FRCP(Glasg), FRCP, FRCP(Edin), of Tallaght ... recipient of the Joseph T. Freeman Award. , This ... is awarded to a prominent physician in the field ... who is a member of the Society,s Health Sciences ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... P. Curran, PhD, of the University of Southern California ... Investigator Award. , This distinguished honor is given for ... biological research. It was established in 1986 to honor ... pioneer in gerontological research at the National Institutes of ...
(Date:8/1/2014)... Society of America (GSA) the nation,s ... aging has chosen Madonna Harrington Meyer, PhD, ... the University of Luxembourg; and Philipp Hessel, MA, ... School of Economics and Political Science as the ... Awards. , These distinguished honors recognize insightful and ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:O'Neill to receive GSA's 2014 Joseph T. Freeman Award 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2
... Feb. 6 SOBeFiT Magazine, the first South Florida,publication ... fitness,nutrition, health and sports for men and women, will ... in South Beach presented by The Sports,Club/LA, as part ... launch. , On February 8th, ...
... PA -- For years controversy has surrounded whether electronic ... cut medical errors, and reduce healthcare costs. Now, researchers ... discovered a way to get another bonus from the ... treatments for disease. , In the first ...
... helping Men stay clean and sober for the past 7 years , we ... , a AA meeting and lots of Food and fellowship,come join us in ... ... one of the finest sober living houses in the country. ...
... ANGELES, Feb. 6 Established in 2004, the Institute ... only non-profit, independent cancer research institute focused on creating ... and metastatic bone disease. Ethan Horwitz, Esq. is ... & Spalding and has an extensive Intellectual Property practice. ...
... finds levels of skepticism correlate with lower cancer screening ... women, especially black women, have more distrust of the ... breast cancer, new research shows. , Almost half of ... or misled by health-care organizations." Eighteen percent strongly agreed ...
... FORT LAUDERDALE, Fla., Feb. 6 The Spherion Employee Confidence ... month,s survey low of 40.4. The Index, which measures workers, ... economic environment, reveals that more workers are confident in their ... (34 percent) reported that they are likely to look for ...
Cached Medicine News:Health News:SOBeFiT Magazine Promotes its Launch With First Annual 5K Run+Walk & Fitness Festival in South Beach 2Health News:SOBeFiT Magazine Promotes its Launch With First Annual 5K Run+Walk & Fitness Festival in South Beach 3Health News:Penn study shows how electronic medical records can be used to test drug efficacy 2Health News:Penn study shows how electronic medical records can be used to test drug efficacy 3Health News:Cleveland House a Sober living Resort, is Celebrating 7 Year Anniversary 2Health News:Minorities Distrust Medical System More 2Health News:Minorities Distrust Medical System More 3Health News:Employee Confidence Index Rises 2.3 Points in January 2Health News:Employee Confidence Index Rises 2.3 Points in January 3Health News:Employee Confidence Index Rises 2.3 Points in January 4Health News:Employee Confidence Index Rises 2.3 Points in January 5
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
... Unlike other ESR products, SEDIPLAST® ... superior design features to protect laboratory ... blood handling. SEDIPLAST® is a uniquely ... which provides greater safety and convenience ...
Medicine Products: